Taken together, this suggests that frequencies of CD39+ Treg in peripheral blood, as well as the ENTPD1 SNPs of each patient may serve as biomarkers to assess the corresponding CD39+ Treg frequencies in colon tumors. This evidence concerns the gene ENTPD1 and colonic neoplasm.